Mycoplasma Testing Market Set $2909.64 Million By 2032,CAGR 13.4%

Mycoplasma Testing Market Size Worth $2909.64 Billion By 2032,CAGR: 13.4%

The global mycoplasma testing market size is expected to reach USD 2909.64 Million by 2032, according to a new study by Polaris Market Research. The report “Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Mycoplasma is a type of bacteria without a cell wall. It is mostly likely to affect the respiratory, urinary, and genital tracts of humans. The presence of stringent regulations and growing concerns about consumer safety is enabling pharmaceutical companies to focus on comprehensive biological testing, including testing of mycoplasma.

A 2023 study published in the Journal of Microbiology focused on exploring advancements in the detection of Mycoplasma genitalium. The recent clearance of molecular-based assays by the U.S. Food and Drug Administration (FDA) permitted diagnostic testing to be widely employed in the United States, making it no longer available only in some laboratories. This is positively influencing the growth of the mycoplasma market.

The emergence of antimicrobial resistance made it difficult to test the presence of mycoplasma in pharmaceutical products and services, which fueled the development of diagnostic tests to determine resistance. Mycoplasma is mostly found in the production phase of biopharmaceutical products, including from the research stage to clinical development, highlighting the need for mycoplasma testing to check safety and accuracy in treating certain diseases.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

The growing research innovations in this field and the adoption of advanced technologies are anticipated to promote the expansion of the mycoplasma testing market. For instance, in November 2023, QIAGEN unveiled its three new QIAcuity kits and software update to expand its product line for polymerase chain reaction technology in cell and gene therapies, the food industry, and the pharmaceutical industry. 

Ongoing expansion activities by biopharmaceutical companies to enhance the quality and safety of their products are positively influencing the mycoplasma testing market. For instance, in November 2023, Bionique, a pharmaceutical lab specializing in protecting medicines from bacteria, expanded its location at Lake Clear, New York, to meet ongoing demand from rapidly growing cell and gene therapies in the region. 

Mycoplasma Testing Market Report Highlights

  • Assays, Kits, & reagents segment is anticipated to witness the highest growth in the coming years due to the need for ready-to-test kits.
  • NAT segment accounted for the largest market share owing to its capability to offer faster results.
  • Cell line testing segment is projected to experience a larger revenue share due to growing biopharmaceutical production.
  • Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the rising innovations in cell and gene therapies.
  • The global players include Agilent Technologies, American Type Culture Collection, Biological Industries Israel Beit Haemek Ltd, & Bionique Testing Laboratories, Inc.

Polaris Market Research has segmented the mycoplasma testing market report based on product & service, technique, application, end user and region:

Mycoplasma Testing, Product & Service Outlook (Revenue - USD Million, 2019 - 2032)

  • Assays, Kits, & Reagents
    • NAT assays, kits, & reagents
    • ELISA assays, kits, & reagents
    • Elimination Kits
    • Stains
    • Other assays, kits, & reagents
  • Instruments
  • Services

Mycoplasma Testing, Technique Outlook (Revenue - USD Million, 2019 - 2032)

  • NAT
  • Staining
  • Other technique

Mycoplasma Testing, Application Outlook (Revenue - USD Million, 2019 - 2032)

  • Cell line testing
  • Virus Testing
  • End-of-Production cell testing

Mycoplasma Testing, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Pharmaceutical & Biotechnology Companies
  • Cell Banks & Laboratories
  • Contract Research Organizations
  • Academic Research Institutes

Mycoplasma Testing, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Mycoplasma Testing Market Report Scope

Report Attributes


Market size value in 2024

USD 1064.00 million

Revenue forecast in 2032

USD 2909.64 million


13.4% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD million and CAGR from 2024 to 2032

Segments covered

  • By Product & Service
  • By Technique
  • By Application
  • By End User
  • By Region

Regional scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Mycoplasma Testing Market Share Analysis (2023)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report